Background. Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravir (DTG)-based regimen may improve lipid profile.
Dolutegravir (DTG) is an integrase strand transfer inhibitor of the human immunodeficiency virus type 1 (HIV-1) [1] [2] [3] [4] and is generally well tolerated with a low potential for drug-drug interactions [5] , an infrequent emergence of resistance mutations [6] , and a neutral lipid profile [7] . In antiretroviral-naive patients, DTG has demonstrated noninferiority to raltegravir [8] and bictegravir [9, 10] and superiority to efavirenz [11] and ritonavir-boosted darunavir [12] and atazanavir [13] .
As the HIV-1-infected population ages, there is a need to identify regimens that reduce the risk of adverse outcomes, such as cardiovascular disease (CVD). Dolutegravir-based regimens may be ideal for this, based on their efficacy and safety profile. Raltegravir may be another choice, but there is some concern about using it as a switch strategy based on the SWITCHMRK results [4] . In the STRIIVING study [14, a switch of suppressed patients to dolutegravir was virologically noninferior, but there was no clear benefit with respect to the lipid profile, due to the lower risk of the study population and the heterogeneity of the baseline regimens. From the perspective of the lipid profile, it may be that the evaluation of a population at higher risk of adverse outcomes and on a regimen that includes a boosted protease inhibitor (with a more unfavorable lipid profile) would identify a population that would benefit more significantly from a switch to DTG.
We performed a randomized, noninferiority, 96-week strategic trial to compare the efficacy of and impact on lipid parameters of immediate switching to DTG (DTG-I group) to that of remaining on a ritonavir-boosted protease inhibitor (PI/r)-based regimen for the first 48 weeks [15] and then a deferred switch to DTG (DTG-D group) in a population with potential high CVD risk.
METHODS

Study Design and Patients
European Network for AIDS Treatment 022 Study (NEAT022) was a randomized, open-label, noninferiority trial conducted in 32 European sites (Supplementary Table 1 ). Patients were recruited between May 2014 and November 2015. Eligible patients were HIV-1-infected adults aged ≥50 years or ≥18 years with a Framingham CVD 10-year risk score >10% [16, 17] . Participants had to be on a stable (>6 months) triple antiretroviral regimen consisting of a PI/r) plus 2 NtRTIs and have a plasma HIV RNA <50 copies/mL for at least the previous 6 consecutive months. See Supplementary Table 2 for details.
Ethics
The trial was conducted in accordance to the Good Clinical Practice and ethical principles of the declaration of Helsinki. The protocol was approved by the ethics committees of all participating hospitals. All participants gave their written informed consent. The study was registered on ClinicalTrials. gov (NCT02098837) and the European Clinical Trials Database (EudraCT: 2013-003704-39).
Randomization and Masking
Eligible participants were randomly assigned (1:1) to either switch to DTG 50 mg/day plus the same 2 nucleotide reverse transcriptase inhibitors (NtRTIs) (DTG-I group) or to continue with the same triple therapy regimen including a PI/r for the first 48 weeks [15] , after which all patients remaining on a PI/r were switched to DTG and followed up to 96 weeks (DTG-D group). We assigned patients to treatment groups by computer-generated permuted blocks of 4 and stratified by country. The study design was open-label.
Study Procedures
Participants attended study centers at screening, baseline, and weeks 4 (DTG group only), 12, 24, 36, 48, 52 (DTG-D group only), 60, 72, 84, and 96. Each visit included a general assessment and collection of blood samples for full blood cell counts plus serum chemistry. CD4 + cell counts and plasma viral loads were measured at screening, baseline, and weeks 24, 48, 72, and 96. Fasting (overnight or >6 hours) serum lipids were measured at all visits. Estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration method [18] . HIV RNA measurements in plasma and, if indicated, testing for antiretroviral resistance by genotype sequencing were done at local laboratories (the local laboratories were required to meet Clinical Laboratory Improvement Amendments regulations or the country's equivalent). Virological failure was defined as 2 consecutive measurements of plasma viral load >50 copies/mL separated at least by 2 weeks during the assigned treatment. A viral blip was defined by a plasma viral load >50 copies/mL of HIV RNA followed by a second measurement <50 copies/mL of HIV RNA. Safety was assessed at all visits by monitoring of all adverse events (AEs) and serious adverse events (SAEs), vital signs, and laboratory values. Adherence during the trial was monitored by participant questioning at each medical visit regarding missed tablets, at any moment during the trial or the prior week. Patients and investigators were advised not to change administration of lipid-lowering agents during the study period unless strictly necessary. Patients were also advised at each medical visit to give up smoking, to exercise daily, to pay attention to their body weight, diet, and alcohol intake, and to control blood pressure using a written predefined healthy lifestyle guidance formulary. AIDS events and deaths, SAEs, AEs grade 3 or above, AEs leading to modification of study drugs, all protocol discontinuations, and all protocol-defined episodes of virological failures required confirmation by an independent endpoint review committee.
Endpoints
The endpoints at 96 weeks were (1) the proportion of patients maintaining treatment response (HIV RNA <50 copies/mL with no discontinuation of the study treatment) and (2) the percentage change from baseline in total cholesterol (TC) to week 96. Nonresponse was defined as any of the following: virological failure, death from any cause, loss to follow-up, consent withdrawal, or permanent change or interruption of randomized treatment for any reason.
Other secondary endpoints were (1) frequency of all clinical and laboratory AEs up to week 96; (2) 
Statistical Analyses
A total of 420 participants (210 per group) was estimated providing at least 90% power to exclude a noninferiority margin of 10% for the difference in proportion of participants reaching the primary endpoint, assuming 90% of participants have treatment success in the DTG-D group at week 48 and a 1-sided α of .025 (2-sided α = .05). The study was powered for the first primary endpoint as this is the criterion that requires the larger sample size.
All patients who underwent randomization were included in the intent-to-treat (ITT) population. In the primary, ITT analysis, the proportion of participants who had treatment success was estimated with Kaplan-Meier methods, censoring at week 96 or last follow-up date. The difference in percentage of participants in treatment success (DTG -PI/r) was estimated and 2-sided 95% confidence intervals (CIs) of the difference were obtained with bootstrap standard error (1000 replicates) as proportions were estimated by time-to-event method.
In the prespecified sensitivity analysis on the per protocol population, individuals were ignored if they did not fulfill the eligibility criteria, withdrew consent, were lost to follow-up, or discontinued study medication for any reasons other than virological failure or AE. DTG-I was considered noninferior to DTG-D if the lower CI bound was below -10% for both ITT and per protocol analyses.
The mean percentage change from baseline in lipid fractions (TC, non-HDL cholesterol, LDL cholesterol, HDL cholesterol, TG, and TC:HDL cholesterol ratio) at week 48 and the mean change from baseline in CD4 + cell counts and eGFR to week 48 were analyzed with the ITT population, with the last observation carried forward approach. The nonparametric Mann-Whitney test was used to compare the changes from baseline between the 2 groups. Subgroup analysis was also conducted to study the treatment effect by PI/r at screening (darunavir, atazanavir, other PI), backbone administration of tenofovir or abacavir, Framingham 10-year CVD risk score (<15% vs ≥15%) [16, 17] , and Framingham CVD 10-year risk score and age (age <50 years and CVD risk >10%, age ≥50 years and CVD risk >10%, age ≥50 years and CVD risk ≤10%) for the 2 co-primary endpoints and all other lipid fractions. Safety analysis was performed with randomized patients who received any study treatment at least once. Any AEs, grade 3 and 4 AEs, antiretroviral therapyrelated AEs (all grade), treatment-modifying AEs (all grade), death, SAEs, and AEs occurring in at least 5% of participants were described and compared by group, using Fisher exact test.
Variables were summarized as proportions for categorical variables (based on the nonmissing sample size), the median and interquartile range for continuous baseline variables, and the mean ± standard deviation for continuous variables used as endpoints. All reported P values are 2-tailed with a significance level of .05. Analyses were performed with IBM SPSS Statistics version 24 and Stata SE version 13 software.
RESULTS
Of the 455 patients screened, 415 (ITT population) were randomized: 205 to switch to a DTG regimen (DTG-I group) and 210 to continue the PI/r regimen for 48 weeks [15] , followed by a deferred switch to DTG (DTG-D group) (Figure 1 and Supplementary Table 1) . At least 1 dose of study treatment was received by 412 patients: 204 in the DTG-I group and 208 in the DTG-D group (Figure 1 ). Baseline characteristics were balanced between groups (Table 1) .
Efficacy
The primary objective of noninferiority at week 48 was met [15] (Figure 2A and 2B) . At week 48, 14 patients in the DTG group and 10 in the PI/r group had experienced treatment failure, corresponding to a treatment success rate of 93.1% and 95.2%, respectively (difference, -2.1% [95% CI, -6.6% to 2.4%]; noninferiority demonstrated). At week 96, 16 patients in the DTG-I group and 27 in the DTG-D group had experienced treatment failure, corresponding to a treatment success rate of 92.2% and 87%, respectively (difference, 5.2% [95% CI, -.6% to 11%]; Figure 2A and Supplementary Figure 1) . The per protocol analysis gave a similar estimated difference of 3% (95% CI, -2.3% to 8.3%; Figure 2B ). Reasons for nonresponse were similar between groups. There were 5 protocol-defined virological failures in the DTG-I group (plasma viral load at failures ranged from 51 to 130 HIV RNA copies/mL) and 5 (of which 1 occurred in the first 48 weeks while receiving PI/r) in the DTG-D group (plasma viral load at failures ranged from 64 to 3373 HIV RNA copies/mL) with no emergent resistance-associated mutations in the 3 of the 10 samples that could be amplified (Supplementary Figure 2) . Of these 10 patients, all but 1 reported 100% adherence at all time points. Subgroup analysis can be seen in Supplementary Figure 3 . Overall, 34 episodes of viral blips occurred in 33 participants (Supplementary Figure 2) . Mean increases in CD4 + cell count from baseline to week 96 were 33 ± 69 cells/µL in the DTG group and 14 ± 185 cells/µL in the PI/r group (P = .18).
Changes in Lipids and in Other CVD Risk Factors
At 96 weeks, TC and other proatherogenic lipid fractions significantly (P < .001) decreased from baseline at similar levels (P > .05) in both the DTG-I and DTG-D groups (TC: -7.8% ± 14.6% vs -5.8% ± 17.7%; LDL cholesterol: -6.9% ± 22.0% vs -4.5% ± 26.5%; non-HDL cholesterol: -10.3% ± 20.5% vs -8.1% ± 23.8%; TC:HDL cholesterol ratio: -6.4% ± 24.4% vs -7.0% ± 23.1%; and TG: -15.6% ± 37.1% vs -12.1% ± 44.1%) (Figure 3 ). Similar significant improvements were detected in both DTG-I and DTG-D groups when analysis of lipid changes was stratified by baseline age and Framingham CVD risk score, by baseline PI/r, and also by backbone administration of tenofovir or abacavir (Supplementary Figure 4A-E) . The change from baseline to week 96 in the percentage of patients receiving lipid-lowering agents, receiving or requiring [19] lipid-lowering agents (Supplementary Figure 5) , currently smoking, taking daily exercise, and with high blood pressure was -0.7%, -5.6%, -2.7%, 6.2%, and 7.5%, respectively, in the DTG-I group and 4.3%, 0%, -4.3%, 6.7%, and 0%, respectively, in the DTG-D group. None of these changes were statistically significant. There was a trend toward a reduction in the CVD risk score at 5 years after 48 weeks of immediate or deferred switching to DTG using both the Framingham [16] or D:A:D Study [17] equations (Supplementary Figure 6) .
Safety
Adverse events, all grades and causalities, were reported in 75% (weeks 0-48) and 77.9% (weeks 48-96) of the patients in the DTG-I arm and in 63.5% (weeks 0-48) and 83.8% (weeks 48-96) in the DTG-D arm, of which 6.4% and 5.8% (DTG-I) and 7.2% and 10.1% (DTG-D), respectively, were SAEs (P > .05; Table 2 ). Eight (3.9%) patients who had received DTG in the DTG-I arm and 9 (4.5%) who had received DTG during weeks 48-96 in the DTG-D arm vs 3 (1.4%) of those who had received PI/r during weeks 0-48 in the DTG-D arm interrupted study medication due to AEs. Mood disturbances or insomnia were the cause of DTG discontinuation in 13 of 17 patients. The most frequent AEs occurring in ≥5% of patients are shown in Table 2 . A major cardiovascular event occurred in 7 patients in the DTG-I arm and in 8 patients in the DTG-D arm, of whom 2 were still receiving a PI/r ( Table 2) . Two death events occurred during the trial in the DTG-D group due to an accidental fall with a temporal bone fracture and a subdural hematoma and to a hepatocellular carcinoma. c Defined as self-reported some exercise (duration not specified) every day.
d An addition of male patients with age ≥50 years or female patients with age >60 years, current or past smoker within the last 3 years, HDL cholesterol <1 mmol/L, high blood pressure, diabetes mellitus, family history of cardiovascular disease. HDL cholesterol level >1.5 mmol/L implicates a subtraction of 1 risk factor. e As estimated by the Chronic Kidney Disease Epidemiology Collaboration method.
Grade 3 or 4 laboratory AEs were observed in 2.5% (weeks 0-48) and 3.7% (weeks 48-96) of the patients in the DTG-I arm and in 14.9% (week 0-48 while still on PI/r) and 5.6% (weeks 48-96) in the DTG-D arm (P < .01 and P = .47; Table 2 ). There was also a small but significant (P < .001) decrease in the calculated eGFR in those who had received DTG (Supplementary Figure 7) .
DISCUSSION
This is the first study to specifically examine switching from a regimen containing 2 NtRTIs plus a PI/r to a regimen with the same backbone plus DTG in virologically stable patients with high CVD risk (61% of the patients were both ≥50 years of age and with a Framingham risk score >10%). The primary objective of noninferiority at week 48 was met [15] . At 96 weeks, the study demonstrated noninferiority for maintenance of control of HIV RNA in the DTG-I group without an overall significant increase in SAEs or in any grade AEs related to antiretroviral therapy. Importantly, in this population we showed significant reduction in proatherogenic lipid fractions.
CVD is a major cause of morbidity and mortality in persons with HIV-1 infection, with an estimated 1.5-to 2.0-fold higher risk compared with the general population [14] . Data from the D:A:D Study showed that CVD accounts for 11% of deaths among HIV-1-infected persons [20] and the EuroSIDA study showed that cardiovascular events account for about one-third of non-AIDS-defining events [21] . The US National Lipid Association [22] suggests that lipid goals be based on the number of risk factors including LDL cholesterol and non-HDL cholesterol and that HIV-1 infection may be counted as a risk factor. Antiretroviral therapy per se [23] [24] [25] or its effect on lipids should also be considered as contributing to risk of CVD [26] . HIV-1 treatment guidelines recommend, in addition to lifestyle changes and lipid-lowering therapy [27] , modifications of antiretroviral regimens for CVD risk reduction [28, 29] . There is good evidence from the general population that reducing TC and LDL cholesterol reduces CVD risk [30] , and there is an ongoing AIDS Clinical Trials Group study in HIV-1-infected patients to examine the cardiovascular impact of adding pitavastatin.
Switching antiretrovirals to improve lipid profiles can be combined with the use of lipid-lowering agents [3, 4, 31, 32] . TC and other proatherogenic lipid fractions significantly improved both after immediate and deferred switching to DTG even when stratified by baseline age, Framingham risk score, and baseline PI/r. Most switching studies have not included in the analysis non-HDL cholesterol, which has been recently incorporated into the National Cholesterol Education Program Adult Treatment Panel III guidelines [19] . Switching to DTG significantly decreased this fraction as well as TC:HDL cholesterol ratio, a factor used in some CVD risk equations, which is usually unaffected in other antiretroviral switch studies [3, 4] . After switching to DTG, a reduction of the LDL cholesterol of >5% (approximately 0.3 mmol per L) from baseline values was achieved. This level of reduction in the general population is associated with a significant reduction in the relative risk of CVD [30] . As 60% of study participants switched away from PI/r regimens containing ritonavir-boosted lopinavir [24] or darunavir [25] , both independently associated with an increased CVD risk, there may be an additional favorable impact. Moreover, there was a trend toward a reduction in the CVD risk scores at 5 years after 48 weeks of immediate or deferred switching to DTG. A limitation of the study was that it was not powered for differences in cardiovascular events, and only 15 major cardiovascular events were observed.
There are some risks associated with switching to a new regimen in stable patients who tolerate well the older medication. In our study, virological failures were numerically more common after both immediate and deferred switching to DTG (9 vs 1 while still on PI/r), albeit all at low level and not associated with emergent resistance mutations. Although there were few discontinuations, there were more after switching to DTG (17 vs 3 while still on PI/r), which is often seen when patients are switching from a regimen that they have been tolerating for a long period of time. Of note, 13 of 17 discontinued due to mood disturbances or insomnia, which have been recently highlighted as potential side effects of DTG [33, 34] . We should also recognize that switching to a single pill of DTG/rilpivirine or DTG/lamivudine would be more appealing in the future. Finally, analysis of patient-related outcomes was not included in the protocol, which was designed >5 years ago. In conclusion, both immediate and deferred switching from a PI/r-based regimen to a DTG regimen in virologically suppressed HIV-infected patients aged ≥50 years or with a Framingham score ≥10% was highly efficacious, was well tolerated, and significantly improved the lipid profile. their families. We thank the NEAT022 study participants and their partners, families, caregivers, and the staff of all the centers taking part in the study. We also thank the European AIDS Treatment Group for collaboration. Spanish centers and Spanish investigators were partially supported by the project RD12/0017 integrated in the Plan Nacional I+D+i and cofunded by the Spanish Instituto de Salud Carlos III (ISCIII)-Subdirección General de Evaluación and European Regional Development Fund (ERDF). We also acknowledge the Spanish HIV Hospital Gregorio Marañon biobank supported by ISCIII, which is integrated in the Spanish AIDS Research Network. 
